期刊文献+

老年早期非小细胞肺癌三维适形放疗的临床分析 被引量:1

Three-dimensional conformal radiotherapy in elderly with early stage non-small cell lung cancer
下载PDF
导出
摘要 目的:观察老年早期非小细胞肺癌患者三维适形放疗的疗效。方法:2002年到2007年,采用三维适形放疗治疗35例老年早期非小细胞肺癌,放疗剂量66-80Gy,中位剂量70Gy,常规分割,2.0Gy/d,年龄71-89岁,中位年龄76岁,其中12例≥80岁。Ⅰ期患者13例,Ⅱ期22例。结果:治疗有效率23例(65.7%)。3年总生存率为28%,中位生存时间38.9个月;3年肿瘤相关生存率为39%,中位生存时间43.5个月。1例(2.9%)患者死于放疗导致的晚期放射性肺损伤,没有观察到其他严重的放疗毒性发生。结论:采用三维适形放疗技术治疗老年早期非小细胞肺癌是安全有效的。 Objective:To investigated the effectiveness of three-dimensional conformal radiotherapy(3D-CRT) alone in elderly patients with early stage(I/II)non-small cell lung cancer(NSCLC).Methods:Between 2002 and 2007,a total of 35 elderly with early stage NSCLC patients were treated by 3DCRT.Radiotherapy doses ranged 6680 Gy(median,70 Gy) using standard fractionation(2.0 Gy per fraction).The age range was 71-89 years(median 76 years) 12 patients ≥80 years old.There were 13(37.1%) stage I and 22(62.9%) stage II patients.Results:Radiographic objective response rate was observed in 23(65.7%) patients.The median survival time was 38.9 months and 3-year survival time was 28%,while the median cancer-related survival time was 43.5 months and a 3-year cancer-related survival rate was 39%.One(2.9%) patient died of RT-induced late lung toxicity,no other high-grade toxicity was observed during this study.Conclusion: 3D-CRT alone was effective and low toxic in elderly with early stage(I/II) NSCLC.
出处 《现代肿瘤医学》 CAS 2011年第9期1761-1764,共4页 Journal of Modern Oncology
关键词 三维适形放疗 非小细胞肺癌 老年人 早期 three-dimensional conformal radiotherapy non-small cell lung cancer elderly early stage
  • 相关文献

参考文献13

二级参考文献33

  • 1李尚文,万永红.26例老年非小细胞肺癌放射治疗临床分析[J].肿瘤研究与临床,2005,17(S1):35-36. 被引量:1
  • 2辛建民,付强,史永铁,李芳琴.三维适形放疗治疗非小细胞肺癌32例疗效观察[J].现代肿瘤医学,2005,13(2):239-240. 被引量:3
  • 3刘天星,董玫,张永敏.65岁以上非小细胞肺癌三维适形放射治疗的疗效观察[J].中国肺癌杂志,2006,9(5):462-464. 被引量:5
  • 4Chen M,Liang GL,Fu XL,et al.The impact of overall treatment time on outcomes in radiation therapy for non-small-cell lung cancer[J].Lung Cancer,2000,28:11-19. 被引量:1
  • 5Sandler AB,Gray R,Brahmer J,et al.Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer[J].N Engl J Med,2006,355:2542-2550. 被引量:1
  • 6Ciuleanu TE,Brodowicz T,Belani CP,et al.Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC:A phase Ⅲ study[J].J Clin Oncol,2008,26 (Suppl):8001. 被引量:1
  • 7Hida T,Okamoto I,Kashii T,et al.Randomized phase Ⅲ study of platinum -double chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in patients(pts) with advanced non-small cell lung cancer(NSCLC):Results of West Japan Thoracic Oncology Group trial (WJTOG)[J].J Clin Oncol,2008,26(Suppl):8012. 被引量:1
  • 8Douillard JY,Hirsh V,Mok T,et al.Molecular and clinical subgroup analyses from a phase Ⅲ trial comparing Gefitinib with docetaxel in previously treated non-small-cell lung cancer[J].J Clin Oncol,2008,26:800. 被引量:1
  • 9El-Shenshawy HM,Fathy A,Eteba S,et al.Sequential chemoradiotherapy versus concurrent chemoradiotherapy plus consolidation chemotherapy in unresectable stage Ⅲ non-small cell lung cancer[J].J Clin Oncol,2008,26:18509. 被引量:1
  • 10Ferrigno D,Buccheri G.Second-line chemotherapy for recurrent nonsmall cell lung cancer:do new agents make a difference[J].Lung Cancer,2000,29:91. 被引量:1

共引文献46

同被引文献16

  • 1Rossi A,Gridelli C. Chemotherapy of advanced non-small cell lung cancer in elderly patients[J].{H}ANNALS OF ONCOLOGY,2006,(z2):58-60. 被引量:1
  • 2Gore E,Movsas B,Santana-Davila R. Evaluation and management of elderly patients with lung cancer[J].{H}Seminars in Radiation Oncology,2012,(04):304-310. 被引量:1
  • 3孙燕;石远凯.临床肿瘤内科手册[M]{H}北京:人民卫生出版社,2007147-149. 被引量:1
  • 4殷蔚伯;余子豪;徐国镇.肿瘤放射治疗学[M]{H}北京:中国协和医科大学出版社,20081350-1374. 被引量:1
  • 5Curran WJ,Paulus R,Langer CJ. Sequential vs. con-current chemoradiation for stage III non-smal celllung can-cer:randomized phase III trial RTOG 9410[J].{H}JOURNAL OF THE NATIONAL CANCER INSTITUTE,2011,(19):1452-1460. 被引量:1
  • 6Domingues PM,Zylberberg R,da Matta de Castro T. Survival data in elderly patients with locally advanced non-small cell lung cancer[J].{H}MEDICAL ONCOLOGY,2013,(01):449. 被引量:1
  • 7Kim JC,Saha D,Cao Q. Enhancement of radiation effects by combined docetaxel and flavopiridol treatment in lung cancer cells[J].{H}Radiotherapy and Oncology,2004,(02):213-221. 被引量:1
  • 8Chen Y,Pandya KJ,Hyrien O. Preclinical and pilot studies of docetaxel chemoradiation for stage III non-small cell lung cancer[J].{H}International Journal of Radiation Oncology Biology Physics,2011,(05):1358-1364. 被引量:1
  • 9Casas F,Vi?olas N,Ferrer F. Long-term results of a phase II trial of induction paclitaxel-carboplatin followed by concurrent radiation therapy and weekly paclitaxel and consolidation paclitaxel-carboplatin in stage III non-small cell lung cancer[J].{H}JOURNAL OF THORACIC ONCOLOGY,2011,(01):79-85. 被引量:1
  • 10Saitoh J,Saito Y,Kazumoto T. Concurrent chemo-radiotherapy followed by consolidation chemotherapy with bi-weekly docetaxel and carboplatin for stage III unresect-able,non-small-cell lung cancer:clinical application of a protocol used in a previous phase II study[J].{H}International Journal of Radiation Oncology Biology Physics,2012,(05):1791-1796. 被引量:1

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部